Letter to the Editor Regarding: Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment

被引：0
|
作者：
Iwahori, Toshiyuki [1 ]
机构：
[1] Eli Lilly Japan KK, Med Dev Unit Japan & Med Affairs, Kobe, Hyogo, Japan
来源：
DIABETES THERAPY | 2020年 / 11卷 / 10期
关键词：
D O I：
10.1007/s13300-020-00899-7
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2441 / 2442
页数：2
相关论文
共 50 条
  • [1] Letter to the Editor Regarding: Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment
    Toshiyuki Iwahori
    [J]. Diabetes Therapy, 2020, 11 : 2441 - 2442
  • [2] Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment
    Brooks, Anne
    Langer, Jakob
    Tervonen, Tommi
    Hemmingsen, Mads Peter
    Eguchi, Kosei
    Bacci, Elizabeth Dansie
    [J]. DIABETES THERAPY, 2019, 10 (02) : 735 - 749
  • [3] Patient Preferences for GLP-1 Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment
    Anne Brooks
    Jakob Langer
    Tommi Tervonen
    Mads Peter Hemmingsen
    Kosei Eguchi
    Elizabeth Dansie Bacci
    [J]. Diabetes Therapy, 2019, 10 : 735 - 749
  • [4] Response to “Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment”
    Anne B. Brooks
    Jakob Langer
    Tommi Tervonen
    Mads Peter Hemmingsen
    Kosei Eguchi
    Elizabeth D. Bacci
    [J]. Diabetes Therapy, 2020, 11 : 2443 - 2446
  • [5] Response to "Letter to the Editor Regarding: Patient Preferences for Glucagon-like Peptide-1 (GLP-1) Receptor Agonist Treatment of Type 2 Diabetes Mellitus in Japan: A Discrete Choice Experiment"
    Brooks, Anne B.
    Langer, Jakob
    Tervonen, Tommi
    Peter Hemmingsen, Mads
    Eguchi, Kosei
    Bacci, Elizabeth D.
    [J]. DIABETES THERAPY, 2020, 11 (10) : 2443 - 2446
  • [6] Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus
    Christensen, Mikkel
    Knop, Filip K.
    Holst, Jens J.
    Vilsboll, Tina
    [J]. IDRUGS, 2009, 12 (08) : 503 - 513
  • [7] NUTRITIONAL INSULIN OR GLP-1 RECEPTOR AGONIST: CROSSROADS IN THE TREATMENT OF TYPE 2 DIABETES MELLITUS
    Garg, Rajesh
    [J]. ENDOCRINE PRACTICE, 2017, 23 (11) : 1357 - 1358
  • [8] Semaglutide GLP-1 receptor agonist Treatment of type 2 diabetes
    Chudleigh, R.
    Bain, S. C.
    [J]. DRUGS OF THE FUTURE, 2017, 42 (08) : 479 - 487
  • [9] Dulaglutide, a GLP-1 receptor agonist, for the treatment of type 2 diabetes
    Clements, Jennifer
    Moore, Katherine
    Shealy, Kayce
    [J]. EXPERT REVIEW OF ENDOCRINOLOGY & METABOLISM, 2015, 10 (06) : 581 - 590
  • [10] Patient Preferences for Diabetes Treatment Among People With Type 2 Diabetes Mellitus in China: A Discrete Choice Experiment
    Huang, Yuankai
    Huang, Qixiang
    Xu, Ailin
    Lu, Mengqing
    Xi, Xiaoyu
    [J]. FRONTIERS IN PUBLIC HEALTH, 2022, 9
12345